Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd versus T-DM1 in high-risk HER2-positive primary breast cancer with residual disease after neoadjuvant therapy
NL-OMON54210Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing T-DXd with T-DM1 (2 arms). Primary endpoint: Invasive disease-free survival. Started Mar 2022; status: recruiting.
02
Drugs
trastuzumab deruxtecantrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON54210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54210.